Reported studies focused exclusively on ASCT in PCNSL
| Reference . | N° . | Median age (range) . | Therapy line . | Therapy (induction ➔ intensification) . | CRR to induction . | Transplanted patients . | Conditioning regimen . | WBRT . | Median follow-up (mo) . | OS . | Neuro- toxicity . | TRM . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17 | 22 | 53 (27-64) | Salvage | ARAC+VP16 | 36% | 91% | Bu/TT/Cy | No | 41 | 3 y: 64% | 32% | 4% |
| 18 | 43 | 52 (23-65) | Salvage | ARAC+VP16 | 35% | 63% | Bu/TT/Cy | No | 36 | 2 y: 45% | 5% | 12% |
| 19 | 45 | 57 (19-72) | Salvage | ICE* | 51% | 40% | Bu/TT | No | 53 | 5 y: 40% | NR | 5% |
| 20 | 28 | 53 (25-71) | First | HD-MTX➔ARAC | 29% | 50% | BEAM | No | 28 | 2 y: 55% | 0% | 4% |
| 21 | 25 | 52 (21-60) | First | MBVP➔IFO+ARAC | 44% | 68% | BEAM | Yes | 34 | 4 y: 64% | 8% | 4% |
| 22 | 6 | 53 (30-66) | First | MBVP➔IFO+ARAC | 2/6 | 6/6† | BEAM | Yes | 41 | 2 y: 40% | 2/6 | 0/6 |
| 23 | 11 | 52 (33-65) | First | HD-MTX➔ARAC | 8/11 | 11/11† | BUCYE | Yes‡ | 25 | 2 y: 89% | 3/11 | 0/11 |
| 24 | 13 | 56 (35-65) | First | MPV➔ARAC | 31% | 46% | LEED | Yes‡ | 44 | 3 y: 76% | 0% | 0% |
| 25 | 23 | 55 (18-69) | First | HD-MTX➔ — | 13% | 69% | Bu/TT | Yes‡ | 15 | 2 y: 48% | 39% | 13% |
| 26 | 33 | 57 (23-67) | First | R-MPV➔ — | 66% | 81% | Bu/TT/Cy | No | 45 | 3 y: 81% | 0% | 12% |
| 27,28 | 21 | 56 (34-69) | First | MPV➔ARAC | 24% | 100%† | Bu/TT/Cy | No | 60 | 5 y: 44% | 0% | 24% |
| 29 | 30 | 54 (27-64) | First | HD-MTX➔ARAC+TT | 33% | 77% | BCNU/TT | Yes | 63 | 5 y: 69% | 17% | 3% |
| 6,30 | 13 | 54 (38-67) | First | HD-MTX➔ARAC+TT | 31% | 85% | BCNU/TT | Yes‡ | 72 | 5 y: 77% | 0% | 0% |
| Reference . | N° . | Median age (range) . | Therapy line . | Therapy (induction ➔ intensification) . | CRR to induction . | Transplanted patients . | Conditioning regimen . | WBRT . | Median follow-up (mo) . | OS . | Neuro- toxicity . | TRM . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17 | 22 | 53 (27-64) | Salvage | ARAC+VP16 | 36% | 91% | Bu/TT/Cy | No | 41 | 3 y: 64% | 32% | 4% |
| 18 | 43 | 52 (23-65) | Salvage | ARAC+VP16 | 35% | 63% | Bu/TT/Cy | No | 36 | 2 y: 45% | 5% | 12% |
| 19 | 45 | 57 (19-72) | Salvage | ICE* | 51% | 40% | Bu/TT | No | 53 | 5 y: 40% | NR | 5% |
| 20 | 28 | 53 (25-71) | First | HD-MTX➔ARAC | 29% | 50% | BEAM | No | 28 | 2 y: 55% | 0% | 4% |
| 21 | 25 | 52 (21-60) | First | MBVP➔IFO+ARAC | 44% | 68% | BEAM | Yes | 34 | 4 y: 64% | 8% | 4% |
| 22 | 6 | 53 (30-66) | First | MBVP➔IFO+ARAC | 2/6 | 6/6† | BEAM | Yes | 41 | 2 y: 40% | 2/6 | 0/6 |
| 23 | 11 | 52 (33-65) | First | HD-MTX➔ARAC | 8/11 | 11/11† | BUCYE | Yes‡ | 25 | 2 y: 89% | 3/11 | 0/11 |
| 24 | 13 | 56 (35-65) | First | MPV➔ARAC | 31% | 46% | LEED | Yes‡ | 44 | 3 y: 76% | 0% | 0% |
| 25 | 23 | 55 (18-69) | First | HD-MTX➔ — | 13% | 69% | Bu/TT | Yes‡ | 15 | 2 y: 48% | 39% | 13% |
| 26 | 33 | 57 (23-67) | First | R-MPV➔ — | 66% | 81% | Bu/TT/Cy | No | 45 | 3 y: 81% | 0% | 12% |
| 27,28 | 21 | 56 (34-69) | First | MPV➔ARAC | 24% | 100%† | Bu/TT/Cy | No | 60 | 5 y: 44% | 0% | 24% |
| 29 | 30 | 54 (27-64) | First | HD-MTX➔ARAC+TT | 33% | 77% | BCNU/TT | Yes | 63 | 5 y: 69% | 17% | 3% |
| 6,30 | 13 | 54 (38-67) | First | HD-MTX➔ARAC+TT | 31% | 85% | BCNU/TT | Yes‡ | 72 | 5 y: 77% | 0% | 0% |
ARAC, cytarabine; BCNU, carmustine; BEAM, carmustine, etoposide, cytarabine, and melphalan; Bu, busulfan; BUCYE, busulfan, cyclophosphamide, and etoposide; CRR, complete remission rate; Cy, cyclophosphamide; ICE (regimen), ifosfamide, carboplatin, and etoposide; IFO, ifosfamide; LEED, cyclophosphamide, etoposide, melphalan, and dexamethasone; MBVP (regimen), methotrexate, carmustine, etoposide, and methylprednisolone; MPV (regimen), methotrexate, vincristine, and procarbazine; N°, assessable patients; OS, overall survival; R-MPV (regimen), MPV plus rituximab; TRM, treatment-related mortality; TT, thiotepa; VP16, etoposide; —, no intensification.
Some patients with relapsed disease were retreated with HD-MTX.
Performed ASCT was a selection criteria.
Only for patients not achieving a CR.